Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH): Oseltamivir Phosphate oral suspension obtains drug registration certificate.

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) announced that the company recently received the "Drug Registration Certificate" for the phosphoric acid oseltamivir suspension issued by the National Medical Products Administration (referred to as "NMPA") (certificate number: 2024S02238). It is reported that the phosphoric acid oseltamivir suspension is an anti-influenza virus drug, mainly used for the treatment of influenza A and B in patients aged 2 weeks and above, as well as for the prevention of influenza A and B in individuals aged 1 year and above.